Diabetes Metab J.  2025 May;49(3):520-521. 10.4093/dmj.2025.0282.

Efficacy and Safety of Automated Insulin Delivery Systems in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis (Diabetes Metab J 2025;49:235-51)

• Fan W
• Deng C
• Zhou Z
• Li X

• KMID: 2567795
• DOI: http://doi.org/10.4093/dmj.2025.0282

Reference

1. Fan W, Deng C, Xu R, Liu Z, Leslie RD, Zhou Z, et al. Efficacy and safety of automated insulin delivery systems in patients with type 1 diabetes mellitus: a systematic review and metaanalysis. Diabetes Metab J. 2025; 49:235–51.

2. Bekiari E, Kitsios K, Thabit H, Tauschmann M, Athanasiadou E, Karagiannis T, et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ. 2018; 361:k1310.

3. Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017; 5:501–12.

4. Biskupiak JE, Ramos M, Levy CJ, Forlenza G, Hopley C, Boyd J, et al. Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States. J Manag Care Spec Pharm. 2023; 29:807–17.

5. Adolfsson P, Heringhaus A, Sjunnesson K, Mehkri L, Bolin K. Cost-effectiveness of the tandem t: Slim X2 with control-IQ technology automated insulin delivery system in children and adolescents with type 1 diabetes in Sweden. Diabet Med. 2024; 41:e15432.

6. Fox DS, Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, et al. Cost-effectiveness of closed-loop automated insulin delivery using the Cambridge hybrid algorithm in children and adolescents with type 1 diabetes: results from a multicenter 6-month randomized trial. J Diabetes Sci Technol. 2024; Mar. 17. [Epub]. https://doi.org/10.1177/19322968241231950.

7. Godoi A, Reis Marques I, Padrao EM, Mahesh A, Hespanhol LC, Riceto Loyola Junior JE, et al. Glucose control and psychosocial outcomes with use of automated insulin delivery for 12 to 96 weeks in type 1 diabetes: a meta-analysis of randomised controlled trials. Diabetol Metab Syndr. 2023; 15:190.

8. Lee TT, Collett C, Bergford S, Hartnell S, Scott EM, Lindsay RS, et al. Automated insulin delivery in women with pregnancy complicated by type 1 diabetes. N Engl J Med. 2023; 389:1566–78.